Skip to main content
. 2021 May 22;394(8):1713–1725. doi: 10.1007/s00210-021-02100-7

Table 1.

Basic characteristics of the study population stratified by the use of HMGRIs

All
N = 3157
Use of HMGRIs
N = 229
No use of HMGRIs
N = 2928
Age (years) * 59.0 ± 7.5 61.9 ± 6.9 58.7 ± 7.5
Women 1675 (53.1) 118 (51.5) 1557 (53.2)
Body mass index (kg/m2) * 27.6 ± 4.3 27.9 ± 3.4 27.6 ± 4.4
Diabetes 359 (11.4) 41 (17.9) 318 (10.9)
Diastolic blood pressure (mmHg) * 81.2 ± 10.6 80.4 ± 9.2 81.3 ± 10.7
Systolic blood pressure (mmHg) * 131.4 ± 19.9 133.6 ± 17.7 131.3 ± 20.1
Antihypertension medication 981 (31.1) 127 (55.5) 854 (29.2)
LDL cholesterol (mg/dL) * 146.3 ± 35.7 129.9 ± 30.2 147.6 ± 35.8
HDL cholesterol (mg/dL) * 59.3 ± 16.9 58.7 ± 17.4 59.3 ± 16.8
Triglycerides (mg/dL) † 121.0 (87.0; 174.0) 138 (100.0; 204.0) 120 (86; 171)
Total cholesterol (mg/dL) * 230.9 ± 38.3 217.2 ± 34.9 232.0 ± 38.3
Non-smoker 1377 (43.6) 103 (45.0) 1274 (43.5)
Past smoker 1080 (34.2) 80 (34.9) 1000 (34.2)
Current smoker 700 (22.2) 46 (20.1) 654 (22.3)
SES (≤ 13 years) 1086 (34.4) 82 (35.8) 1004 (34.3)
CAC score at baseline † 7.5 (0.0; 98.8) 61.4 (2.8; 279.8) 6.2 (0; 84)
CAC score at first follow-up † 27.9 (0; 202.2) 142.9 (22.4; 561.9) 24 (0; 182.3)
Slow progression of CAC 392 (12.4) 16 (7.0) 376 (12.8)
Expected progression of CAC 2147 (68.0) 143 (62.5) 2004 (68.4)
Rapid progression of CAC 618 (19.6) 70 (30.6) 548 (18.7)
Weighted GRS * 0.0498 ± 0.005 0.0497 ± 0.0047 0.0499 ± 0.005

LDL low-density lipoprotein, HDL high-density lipoprotein, SES socioeconomic status, CAC coronary artery calcification, GRS genetic risk score. Data are given as number (percentage) unless otherwise indicated. * Data are given as the mean ± SD. Data are given as the median (Q1; Q3).